Burning Rock Biotech (NASDAQ:BNR) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Burning Rock Biotech (NASDAQ:BNR) from a buy rating to a hold rating in a report released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Burning Rock Biotech Price Performance

NASDAQ:BNR opened at $24.48 on Friday. Burning Rock Biotech has a 12-month low of $2.18 and a 12-month high of $24.48. The firm has a market cap of $263.40 million, a price-to-earnings ratio of -14.75 and a beta of 1.25. The company’s 50-day moving average is $17.25 and its two-hundred day moving average is $10.80. The company has a current ratio of 3.14, a quick ratio of 2.91 and a debt-to-equity ratio of 0.03.

Hedge Funds Weigh In On Burning Rock Biotech

Several institutional investors and hedge funds have recently bought and sold shares of BNR. China Universal Asset Management Co. Ltd. purchased a new position in Burning Rock Biotech during the third quarter worth approximately $26,000. Prospera Financial Services Inc acquired a new stake in shares of Burning Rock Biotech during the 3rd quarter worth $214,000. Finally, Crcm LP raised its position in shares of Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the period. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.